Adrenoleukodystrophy (ALD) Completed Phase 2 Trials for Alemtuzumab (DB00087)

IndicationStatusPhase
DBCOND0045881 (Adrenoleukodystrophy (ALD))Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01043640Allogeneic Bone Marrow Transplant for Inherited Metabolic DisordersTreatment